These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 19647775)

  • 1. A novel DPP-IV-resistant analog of glucagon-like peptide-1 (GLP-1): KGLP-1 alone or in combination with long-acting PLGA microspheres.
    Gao Z; Tang Y; Chen J; Bai R; Zhang Q; Hou Y; Lu Y; Bai G
    Peptides; 2009 Oct; 30(10):1874-81. PubMed ID: 19647775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
    Green BD; Gault VA; O'Harte FP; Flatt PR
    Diabetes Obes Metab; 2005 Sep; 7(5):595-604. PubMed ID: 16050953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the subchronic antidiabetic effects of DPP IV-resistant GIP and GLP-1 analogues in obese diabetic (ob/ob) mice.
    Irwin N; McClean PL; Flatt PR
    J Pept Sci; 2007 Jun; 13(6):400-5. PubMed ID: 17486662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of therapeutic potentials of site-specific PEGylated glucagon-like peptide-1 isomers as a type 2 anti-diabetic treatment: Insulinotropic activity, glucose-stabilizing capability, and proteolytic stability.
    Youn YS; Chae SY; Lee S; Jeon JE; Shin HG; Lee KC
    Biochem Pharmacol; 2007 Jan; 73(1):84-93. PubMed ID: 17054919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Function of a long-term, GLP-1-treated, insulin-secreting cell line is improved by preventing DPP IV-mediated degradation of GLP-1.
    Green BD; Liu HK; McCluskey JT; Duffy NA; O'Harte FP; McClenaghan NH; Flatt PR
    Diabetes Obes Metab; 2005 Sep; 7(5):563-9. PubMed ID: 16050949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV.
    Drucker DJ; Shi Q; Crivici A; Sumner-Smith M; Tavares W; Hill M; DeForest L; Cooper S; Brubaker PL
    Nat Biotechnol; 1997 Jul; 15(7):673-7. PubMed ID: 9219272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucagon-like peptide 1 (GLP-1) secretion and plasma dipeptidyl peptidase IV (DPP-IV) activity in morbidly obese patients undergoing biliopancreatic diversion.
    Lugari R; Dei Cas A; Ugolotti D; Barilli AL; Camellini C; Ganzerla GC; Luciani A; Salerni B; Mittenperger F; Nodari S; Gnudi A; Zandomeneghi R
    Horm Metab Res; 2004 Feb; 36(2):111-5. PubMed ID: 15002062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation of glucagon-like peptide-1 loaded PLGA microspheres: characterizations, release studies and bioactivities in vitro/in vivo.
    Yin D; Lu Y; Zhang H; Zhang G; Zou H; Sun D; Zhong Y
    Chem Pharm Bull (Tokyo); 2008 Feb; 56(2):156-61. PubMed ID: 18239299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemoenzymatic synthesis of glycosylated glucagon-like peptide 1: effect of glycosylation on proteolytic resistance and in vivo blood glucose-lowering activity.
    Ueda T; Tomita K; Notsu Y; Ito T; Fumoto M; Takakura T; Nagatome H; Takimoto A; Mihara S; Togame H; Kawamoto K; Iwasaki T; Asakura K; Oshima T; Hanasaki K; Nishimura S; Kondo H
    J Am Chem Soc; 2009 May; 131(17):6237-45. PubMed ID: 19361194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice.
    Green BD; Lavery KS; Irwin N; O'harte FP; Harriott P; Greer B; Bailey CJ; Flatt PR
    J Pharmacol Exp Ther; 2006 Aug; 318(2):914-21. PubMed ID: 16648370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incretins and other peptides in the treatment of diabetes.
    Todd JF; Bloom SR
    Diabet Med; 2007 Mar; 24(3):223-32. PubMed ID: 17263764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Analogs of glucagon-like peptide-1 (GLP-1): an old concept as a new treatment of patients with diabetes mellitus type 2].
    Diamant M; Bunck MC; Heine RJ
    Ned Tijdschr Geneeskd; 2004 Sep; 148(39):1912-7. PubMed ID: 15495988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel GLP-1 analog, BPI3006, with potent DPP IV resistance and good glucoregulatory effect.
    Li C; Huan Y; Shen N; Ji L; Sun S; Liu S; Liu Q; Gao L; Tan F; Wang Y; Shen Z
    Biochem Biophys Res Commun; 2010 Oct; 400(4):563-8. PubMed ID: 20804731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice.
    Kim SJ; Nian C; Doudet DJ; McIntosh CH
    Diabetes; 2008 May; 57(5):1331-9. PubMed ID: 18299314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 7-But-2-ynyl-9-(6-methoxy-pyridin-3-yl)-6-piperazin-1-yl-7,9-dihydro-purin-8-one is a novel competitive and selective inhibitor of dipeptidyl peptidase IV with an antihyperglycemic activity.
    Yamazaki K; Yasuda N; Inoue T; Nagakura T; Kira K; Shinoda M; Saeki T; Tanaka I
    J Pharmacol Exp Ther; 2006 Dec; 319(3):1253-7. PubMed ID: 16980568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preparation, characterization, and application of biotinylated and biotin-PEGylated glucagon-like peptide-1 analogues for enhanced oral delivery.
    Chae SY; Jin CH; Shin HJ; Youn YS; Lee S; Lee KC
    Bioconjug Chem; 2008 Jan; 19(1):334-41. PubMed ID: 18078308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incretin mimetics and dipeptidyl peptidase-IV inhibitors: potential new therapies for type 2 diabetes mellitus.
    Triplitt C; Wright A; Chiquette E
    Pharmacotherapy; 2006 Mar; 26(3):360-74. PubMed ID: 16503716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engineered glucagon-like peptide-1-producing hepatocytes lower plasma glucose levels in mice.
    Riedel MJ; Lee CW; Kieffer TJ
    Am J Physiol Endocrinol Metab; 2009 Apr; 296(4):E936-44. PubMed ID: 19190262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats.
    Burkey BF; Li X; Bolognese L; Balkan B; Mone M; Russell M; Hughes TE; Wang PR
    J Pharmacol Exp Ther; 2005 Nov; 315(2):688-95. PubMed ID: 16027230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liposomal formulations of glucagon-like peptide-1: improved bioavailability and anti-diabetic effect.
    Hanato J; Kuriyama K; Mizumoto T; Debari K; Hatanaka J; Onoue S; Yamada S
    Int J Pharm; 2009 Dec; 382(1-2):111-6. PubMed ID: 19698772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.